Skip to main content

Table 4 Treatment-related adverse events and causes of chemotherapy interruptions

From: Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach

  FOLFIRINOX (n = 371) Gemcitabine/nab-paclitaxel (n = 157) P value FOLFIRINOX (n = 151) Gemcitabine/nab-paclitaxel (n = 151) P value
Treatment-related adverse events
 Anemia ≥3 70 (18.9) 50 (31.8) <  0.01 29 (19.2) 50 (33.1) 0.01
 Thrombocytopenia ≥3 48 (12.9) 15 (9.6) 0.27 22 (14.6) 15 (9.9) 0.22
 Neutropenia ≥3 181 (48.8) 70 (44.6) 0.38 78 (51.7) 67 (44.4) 0.21
 Neutropenic fever 48 (12.9) 10 (6.4) 0.03 15 (9.9) 10 (6.6) 0.30
 Granulocyte colony stimulating factor 304 (81.9) 10 (6.4) <  0.001 130 (86.1) 9 (6.0) <  0.001
 Peripheral neuropathy 56 (15.1) 40 (25.5) <  0.01 25 (16.6) 38 (25.2) 0.07
Cause of chemotherapy interruption 25 (6.7) 46 (29.3) <  0.001 12 (7.9) 35 (23.2) < 0.001
 General weakness 21 (5.6) 22 (14.0)   10 (6.6) 19 (12.6)  
 Peripheral neuropathy 0 15 (9.6)   0 8 (5.3)  
 Peripheral edema 0 3 (1.9)   0 3 (2.0)  
 Uncontrolled diarrhea 1 (0.3) 1 (0.6)   0 1 (0.7)  
 Drug-induced pneumonitis 0 2 (1.3)   0 1 (0.7)  
 Bone marrow suppression 3 (0.8) 1 (0.6)   2 (1.3) 1 (0.7)  
 Others (pneumonia, tumor bleeding) 0 2 (1.3)   0 2 (1.4)